ENOV · Enovis CORP
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.31B – $2.37B | $2.3B | $2.25BG | $2.11BG | $1.71BG | $1.56B | $1.43B | $1.12B | $3.33B | $2.19B | $1.94B | $3.19B | $3.43B | $4.62B | $4.21B | $3.91B | $693.39M | $541.99M | $525.02M | |
| — | $893.54M | $902.79M | $926.87M | $716.42M | $693.72M | $648.51M | $517.06M | $1.93B | $1.46B | $1.27B | $2.19B | $2.36B | $3.15B | $2.9B | $2.76B | $453.29M | $350.58M | $339.24M | |
| — | $1.4B | $1.35B | $1.18B | $990.78M | $869.38M | $777.68M | $603.64M | $1.4B | $729.38M | $671.58M | $992.38M | $1.07B | $1.48B | $1.31B | $1.15B | $240.1M | $191.41M | $185.79M | |
| — | — | 59.84% | 56.02% | 58.04% | 55.62% | 54.53% | 53.86% | 42.11% | 33.26% | 34.67% | 31.15% | 31.2% | 31.98% | 31.05% | 29.44% | 34.63% | 35.32% | 35.39% | |
| — | $124.32M | $120.33M | $91.3M | $75.33M | $60.83M | $49.09M | $34.27M | — | — | — | — | — | — | — | — | $5.71M | $6.21M | $5.93M | |
| — | $1.08B | $1.07B | $1.03B | $830.31M | $772.91M | $665.78M | $515.47M | $1.13B | $548.76M | $500.65M | $696.8M | $748.34M | $1.01B | $864.33M | $908.44M | $162.76M | $133.51M | $112.5M | |
| — | $172.34M | $173.65M | $165.53M | $133.52M | $126.3M | $116.92M | $103.31M | $135.8M | $43.7M | $39.8M | $57.37M | $56.76M | $67.05M | $41.01M | $85.11M | — | — | — | |
| — | $1.35B | $1.34B | $927.83M | $217.11M | $202.97M | $186.99M | $167.9M | $215.61M | $81.21M | $72.69M | $128.83M | $137.04M | $174.72M | $119.26M | $183.4M | $22.6M | $16.81M | — | |
| — | $12.78M | $9.79M | $27.29M | $17.34M | $17.23M | $8.69M | $16.78M | $65.3M | $77.69M | $68.35M | $58.5M | $56.82M | $58.12M | $35.5M | $60.06M | $9.68M | $10.32M | $18.18M | |
| — | -$1.04B | -$1.12B | -$775.72M | -$65.71M | -$71.18M | -$62.8M | -$66.18M | $203.61M | $151.54M | $135.6M | $236.85M | $265.62M | $409.55M | $406.39M | $140.01M | $25.91M | $34.37M | $39.63M | |
| — | — | -50.01% | -36.81% | -3.85% | -4.55% | -4.4% | -5.91% | 6.12% | 6.91% | 7% | 7.43% | 7.73% | 8.86% | 9.66% | 3.58% | 3.74% | 6.34% | 7.55% | |
| — | $308.8M | $219.89M | $152.11M | $151.4M | $131.79M | $124.19M | $101.72M | $419.22M | $232.74M | $208.29M | $365.68M | $402.66M | $584.28M | $525.65M | $323.41M | $48.5M | $51.18M | — | |
| — | $33.55M | $34.82M | $57.1M | $19.75M | $24.05M | $29.11M | $52.82M | $119.5M | $49.08M | $40.11M | $30.28M | $47.5M | $51.31M | $103.6M | $91.57M | $5.92M | $6.68M | $7.21M | |
| — | $1.95M | -$367K | $9.9M | $25.66M | $2.09M | $0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | -$600K | -$600K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | -$29.87M | $0 | $0 | -$10.13M | $0 | $0 | — | — | — | — | — | — | — | |
| — | -$1.07B | -$1.16B | -$822.92M | -$67.13M | -$2.07M | -$121.78M | -$119.01M | $50.49M | $92.36M | $48.56M | $206.52M | $218.12M | $358.25M | $302.8M | $48.44M | $19.99M | $27.69M | $32.42M | |
| — | $30.81M | $22.29M | $4.49M | -$13.29M | $36.12M | -$19.53M | -$44.58M | $31.63M | -$29.51M | $2.48M | $51.77M | $41.17M | -$62.03M | $93.65M | $90.7M | $15.43M | $11.47M | $8.62M | |
| — | -$1.1B | -$1.18B | -$825.49M | -$33.26M | -$13.29M | $71.66M | $42.63M | -$527.65M | $140.2M | $151.09M | $128.11M | $167.74M | $392.1M | $178.63M | -$64.4M | $4.56M | $16.22M | $23.8M | |
| — | — | -52.69% | -39.17% | -1.95% | -0.85% | 5.02% | 3.8% | -15.86% | 6.39% | 7.8% | 4.02% | 4.88% | 8.48% | 4.25% | -1.65% | 0.66% | 2.99% | 4.53% | |
| — | $4.69M | — | — | — | — | $4.62M | $3.15M | $10.5M | $14.28M | $18.42M | $17.08M | $19.44M | $28.18M | $30.52M | $22.14M | $0 | $0 | — | |
| — | -$13.29M | — | — | — | — | — | — | — | $168.55M | $44.5M | $137.67M | $157.51M | $370.19M | $158.23M | -$83.35M | $4.56M | $16.22M | — | |
| — | -$1.13B | -$1.15B | -$927.93M | -$4.71M | -$50.69M | $7.75M | $74.36M | -$195.99M | -$60.46M | $565.06M | -$173.52M | -$75.29M | -$4.05M | $279M | -$37.56M | -$35.72M | -$4.5M | $32.86M | |
| USD/shares | — | -$19.30 | -$20.75 | -$14.93 | -$0.61 | -$0.25 | $1.40 | $0.93 | -$6.70 | $2.01 | $2.12 | $1.79 | $2.32 | $5.27 | $2.69 | -$1.58 | $0.17 | $0.64 | — |
| USD/shares | $3.52 – $3.73* | -$19.30 | -$20.75G | -$14.93G | -$0.61G | -$0.25 | $1.40 | $0.93 | -$6.70 | $2.00 | $2.10 | $1.79 | $2.31 | $5.20 | $2.65 | -$1.58 | $0.17 | $0.64 | — |
| shares | — | — | 57.07M | 55.28M | 54.49M | 54.07M | 51.14M | 45.59M | 78.85M | 69.89M | 71.6M | 71.41M | 72.1M | 70.38M | 57.63M | 52.91M | 25.35M | 25.21M | — |
| shares | — | — | 57.07M | 55.28M | 54.49M | 54.07M | 51.14M | 45.59M | 79.4M | 70.18M | 72.04M | 71.58M | 72.55M | 71.27M | 58.31M | 52.91M | 25.72M | 25.37M | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2010–FY2025: $256.46M in buybacks, $205K in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 63 similar-size Medical Devices companies (of 143 listed).
EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA (non-GAAP)”, extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.
Valuation over time computed as of each quarter's filing date
EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA (non-GAAP)”, extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Prevention and Recovery | $1,136,968,000 | $1,097,957,000 | $1,076,776,000 | $1,027,628,000 | $1,026,029,000 | $863,150,000 | — | — |
| Reconstructive Segment | $1,111,081,000 | $1,009,666,000 | $630,421,000 | $535,473,000 | $400,159,000 | $257,550,000 | — | — |
| Fabrication Technology | — | — | — | — | — | — | $2,247,026,000 | $2,193,083,000 |
| Medical Technology | — | — | — | — | — | — | $1,080,432,000 | $0 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $1,295,333,000 | $1,245,676,000 | $1,152,360,000 | $1,062,765,000 | $1,030,440,000 | $839,972,000 | $1,464,152,000 | $540,533,000 |
| Foreign | $952,716,000 | $861,947,000 | $554,837,000 | $500,336,000 | $395,748,000 | $280,728,000 | $1,863,306,000 | $1,652,550,000 |
By Product & Service (USD)
| Component | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Consumable Products | $1,669,848,000 | $1,342,565,000 | $1,544,002,000 | $1,569,096,000 | $1,380,152,000 |
| Prevention Rehabilitation | $1,026,029,000 | $863,150,000 | $845,890,000 | — | — |
| Equipment Products | $758,267,000 | $607,504,000 | $703,024,000 | $623,987,000 | $557,130,000 |
| Reconstructive | $400,159,000 | $257,550,000 | $234,542,000 | — | — |